ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel.
On Tuesday, September 15, 2026, Joshua Lev, Co-CEO, President and CFO, will participate in a fireside chat and host one-on-one meetings with investors during the conference.
Investors who wish to request a meeting should contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations at [email protected].
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
[email protected]
